Siolta Therapeutics is a technology company.
Siolta Therapeutics has raised $42.0M across 2 funding rounds.
Siolta Therapeutics has raised $42.0M in total across 2 funding rounds.
Siolta Therapeutics is a clinical-stage biotechnology company specializing in the development of microbiome-based live biotherapeutics and companion diagnostics aimed at the prevention and treatment of chronic inflammatory diseases, with a current focus on allergic asthma and atopic diseases. Their lead product, STMC-103H, is a multi-strain live biotherapeutic in phase 2 clinical trials targeting the prevention of atopic diseases such as asthma, food allergies, and atopic dermatitis. Siolta serves patients impacted by immune-related inflammatory conditions by leveraging deep scientific insights into the infant gut microbiome and immune tolerance mechanisms to create precision microbial therapies. The company has demonstrated growth momentum through successful clinical progress and recent financing rounds, including a $12 million Series C in 2024 to advance their pipeline[1][2][4][5].
Founded in 2016 by Susan Lynch (UCSF), Nikole Kimes (CEO, formerly UCSF), and Samir Kaul (Khosla Ventures), Siolta emerged from academic research on the maternal-infant microbiome axis and immunomodulatory molecules derived from gut organisms. The founders combined strong scientific expertise with venture-backed startup experience to translate microbiome science into therapeutic products. Early traction included advancing their lead candidate into clinical development and securing funding to scale manufacturing and R&D capabilities[2][3][4].
Siolta is positioned at the forefront of the microbiome therapeutics revolution, riding the growing trend of leveraging the human microbiome to develop novel treatments for immune and inflammatory diseases. The timing is critical as advances in microbiome science, bioinformatics, and anaerobic culturing converge with unmet medical needs in allergy and autoimmune conditions. Market forces favor precision, biologically based therapies that can prevent disease onset, reducing healthcare burdens. Siolta’s approach exemplifies the shift from symptom management to disease prevention through ecosystem-based, personalized medicine, influencing both biotech innovation and clinical practice paradigms[1][4][6].
Looking ahead, Siolta Therapeutics is expected to continue advancing its lead candidate through late-stage clinical trials, with potential expansion into additional inflammatory and autoimmune indications. Trends shaping their journey include increasing acceptance of live biotherapeutics, regulatory clarity around microbiome-based drugs, and growing demand for preventive medicine. Their influence may expand as they validate microbiome-driven precision therapies, potentially setting new standards for treating chronic inflammatory diseases. Siolta’s integration of cutting-edge science with scalable manufacturing and clinical development positions them as a key player in the future of microbiome-based medicine[1][2][5].
Siolta Therapeutics has raised $42.0M in total across 2 funding rounds.
Siolta Therapeutics's investors include Khosla Ventures, Sanofi Ventures, Alliance of Angels, LAUNCH, George Godula, Kurt Bilafer, Matthew Dellavedova, Stephen Garden.
Siolta Therapeutics has raised $42.0M across 2 funding rounds. Most recently, it raised $12.0M Series C in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $12.0M Series C | Khosla Ventures, Sanofi Ventures | |
| Sep 1, 2020 | $30.0M Series B | Alliance of Angels, Khosla Ventures, LAUNCH, Sanofi Ventures, George Godula, Kurt Bilafer, Matthew Dellavedova, Stephen Garden |